Healio Visionary Medicine: The Next Era of Retinal Disease Treatment & Patient Adherence – Neovascular Age-Related Macular Degeneration (nAMD)

Key Features

Evaluate the benefits of newly available anti-VEGF treatment options for DR and DME that may improve visual outcomes.

Topics Covered

Diabetic Macular Edema (DME)

Learning Objectives

• Discuss consequences of delayed or inter­rupted treatment for nAMD
  
• Describe efficacy and safety of newer anti-VEGF treatments for nAMD

Target Audience

The target audience includes retina specialists as well as comprehensive ophthalmologists.

Additional credit info

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and DKBmed LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education
Partners designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.

PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until 11/25/26. PAs should only claim credit commensurate with the extent of their participation.